TNF and juvenile idiopathic arthritis: Furthermore, the products of these monocyte/macrophages are the targets of several therapeutics used to treat JIA, such as TNFα inhibitors etanercept and adalimumab, IL-1β receptor antibody anakinra, and IL-6 receptor antibody tocilizumab (15).